A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.

Investigator: Tetsuo Ashizawa, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT03701399


Protocol Number: Pro00020426


The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
More to Explore